Vir Biotechnology, Inc. (VIR) FY2026 YTD Q2 P&L / Income Statement

Vir Biotechnology, Inc. (VIR) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues

238,917,000 US dollars

Cost of revenue

0 US dollars

Gross profit (calculated)

238,917,000 US dollars

Operating expenses (calculated)

297,740,000 US dollars

Income (loss) from operations

negative 58,823,000 US dollars

Total other income

13,557,000 US dollars

Income (loss) before provision for income taxes

negative 45,266,000 US dollars

Provision for income taxes

349,000 US dollars

Net income (loss)

negative 45,615,000 US dollars

License and collaboration revenue

238,894,000 US dollars

Grant revenue

23,000 US dollars

Other revenue

0 US dollars

Research and development

244,205,000 US dollars

Selling, general and administrative

53,535,000 US dollars

Restructuring, long-lived assets impairment and related charges, net

0 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.